ResMed Inc. (NYSE:RMD) is popular among institutional investors owning 72%, marking it a top growth stock for the long-term. Despite some recent weakness in stock, the company's financials remain strong, with a 52% boost in profit and record margins. Expectations for future growth are high, with ResMed slated to report Q2 fiscal 2025 earnings in January 2025. Despite a slight drop in organic sales, emerging 'Mega Trends' could provide the needed boost. The last five years have seen a 7.2% CAGR for the company's share, making it an attractive growth stock. It's new brand evolution strategy also promises potential benefits. Despite superior Q4 sales, the stock experienced a drop. The company's revenue increased by 10% in Q2, with some questions remaining about its GLP-1 products. ResMed has a high institutional ownership of 74%, indicating trust from the big guns. However, recent insider shares sales might suggest hesitancy on their part. Eli Lilly's new obesity drug, recently approved in sleep apnea, could pose a threat to ResMed's market share. Ongoing strong financial performance, new product developments and participation in high-profile conferences continue to be noted. However, possible regulatory challenges and competitive threats could cast a cloud over the stock.
Resmed RMD News Analytics from Mon, 24 Jun 2024 07:00:00 GMT to Sat, 22 Mar 2025 13:06:42 GMT -
Rating 3
- Innovation 6
- Information 5
- Rumor 2
